Commentary I: Pathophysiologic construct for neuronal degeneration/ regeneration in multiple sclerosis

Neurology

Volumn 68, Issue 22 SUPPL. 3, 2007, Pages

  Birnbaum, Gary ^a   Leist, Thomas P ^b   Lublin, Fred D ^c  

^a Minneapolis Clinic of Neurology   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN PROTECTION; CLINICAL FEATURE; CONFERENCE PAPER; DEMYELINATION; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; REMYELINIZATION; T LYMPHOCYTE ACTIVATION;

EID: 34249814916     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000275226.67269.a3     Document Type: Conference Paper

References (18)

1. Lisak RP. Neurodegeneration in multiple sclerosis: defining the problem. Neurology 2007;68(suppl 3):S5-S12.
2. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007;68(suppl 3):S13-S21.
3. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68(suppl 3):S22-S31.
4. Yong VW, Giuliani F, Xue M, Bar-Or A, Metz LM. Experimental models of neuroprotection relevant to multiple sclerosis. Neurology 2007;68(suppl 3):S32-S37.
5. Loeb JA. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology 2007;68(suppl 3):S38-S42.
6. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
7. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006;108:327-332.
8. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006;129:1507-1516.
9. Metz I, Lucchinetti CF, Openshaw H, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007;130(Pt 5):1254 -1262.
10. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-468.
11. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-979.
12. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993;33:137-151.
13. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-2712.
14. Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125:1297-1308.
15. Popovic N, Schubart A, Goetz BD, et al. Inhibition of autoimmune encephalomyelitis by tetracycline. Ann Neurol 2002;51:215-223.
16. Wells JEA, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;126:1628-1637.
17. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis [letter]. Ann Neurol 2004;55:756.
18. Thoenen H, Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 2002;5(suppl):1046-1050.